

1 **Performance of different nebulizers in clinical use for**
2 **Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)**

3
4 Short title: Technical characterisation of PIPAC nebulizers

5
6 Daniel Göhler, Dipl.-Ing.^{1,2}, Kathrin Oelschlägel, Dipl.-Ing¹, Mehdi Ouaiissi, Prof, MD,
7 PhD^{3,4}, Urs Giger-Pabst, Prof, MD^{3,5}

8
9 ¹ Topas GmbH, Dresden, Germany

10 ² Research Group Mechanical Process Engineering, Institute of Process Engineering and
11 Environmental Technology, Technische Universität Dresden, Dresden, Germany

12 ³ EA4245 Transplantation, Immunology, Inflammation, Université de Tours, France

13 ⁴ Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver
14 Transplant Surgery, University Hospital of Tours, France

15 ⁵ Fliedner Fachhochschule, University of Applied Science Düsseldorf, Düsseldorf, Germany

16
17
18 **Corresponding author:**

19 Urs Giger-Pabst, MD

20 University of Applied Science

21 Fliedner Fachhochschule

22 Geschwister-Aufricht-Straße 9

23 40489 Düsseldorf, Germany

24 E-Mail: ursgiger@gmx.net

25 Phone: +49 163 729 44 07

26
27
28 **Key words**

29 Pressurized Intraperitoneal Aerosol Chemotherapy, PIPAC, aerosol droplet size, gravimetry,

30 Nebulizer, MCR-4 Topol[®], HurriChem[™], QuattroJet

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 **Author Contributions**

33 Daniel Göhler and Urs Giger-Pabst: study design, experiments, data acquisition, data
34 interpretation and drafting of manuscript.

35 Kathrin Oelschlägel and Mehdi Ouaiissi: critical revision for important intellectual content of
36 the manuscript according to their field of research.

37 **Disclosure**

38 Strictly academic study supported by institutional funds. All authors have no conflicts of
39 interest or financial ties to declare.

40 **Data Availability Statement**

41 All relevant data are within the manuscript. Raw data will be provided by the corresponding
42 author upon request.

43 **Legal background**

44 Purely technical analyses without the use of biological material or patients requiring no specific
45 legal authorization or ethics vote.

46 **Acknowledgments**

47 The authors thank Professor Marc Pocard, Hepato-Biliary-Pancreatic Gastrointestinal Surgery
48 and Liver Transplantation, Pitié Salpêtrière Hospital, AP-HP, F-75013 Paris, France, for
49 providing a HurriChem™ (ThermaSolutions, White Bear Lake, MN, USA) nozzle.

50

51 **Abstract**

52 *Objective:* Technical ex-vivo comparison of commercial nebulizer nozzles used for Pressurized
53 Intraperitoneal Aerosol Chemotherapy (PIPAC).

54 *Methods:* The performance of four different commercial nebulizer nozzles (Nebulizer;
55 HurriChem™; MCR-4 TOPOL®; QuattroJet) was analysed concerning: i) technical design and
56 principle of operation, ii) operational pressure as function of the liquid flow rate, iii) droplet
57 size distribution via laser diffraction spectrometry, iv) spray cone angle, spray cone form as
58 well as horizontal drug deposition by image-metric analyses and v) chemical resistance via
59 exposing to a cytostatic solution and chemical composition by means of spark optical emission
60 spectral analysis.

61 *Results:* The Nebulizer shows quasi an identical technical design and thus also a similar
62 performance (e.g., mass median droplet size of 29 µm) as the original PIPAC nozzles (MIP/
63 CapnoPen). All other nozzles show more or less a performance deviation to the original PIPAC
64 nozzles. The HurriChem™ has a similar design and principle of operation as the Nebulizer, but
65 provides a finer aerosol (22 µm). The principle of operation of MCR-4 TOPOL® and QuattroJet
66 differ significantly from that of the original PIPAC nozzle technology. The MCR-4 TOPOL®
67 offers a hollow spray cone with significantly larger droplets (50 µm) than the original PIPAC
68 nozzles. The QuattroJet generates an aerosol (22 µm) similar to that of the HurriChem™ but
69 with improved spatial drug distribution.

70 *Conclusion:* The availability of new PIPAC nozzles is encouraging but can also have a negative
71 impact if their performance and efficacy is unknown. It is recommended that PIPAC nozzles
72 that deviate from the current standard should be subject to bioequivalence testing and
73 implementation in accordance with the IDEAL-D framework prior to routine clinical use.

74

75 **1 Introduction**

76 More than a decade ago, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) was
77 introduced clinically as a new approach to deliver intraperitoneal chemotherapy to patients
78 suffering from end-stage peritoneal surface malignancies. Using a high-pressure injector
79 connected to a specially designed PIPAC nozzle, liquid chemotherapeutic drugs are aerosolised
80 during laparoscopic surgery within the capnoperitoneum. This approach is expected to have a
81 better spatial distribution pattern, greater depth of penetration, and higher drug concentration in
82 the tissue than conventional liquid intraperitoneal chemotherapy [1, 2]. Clinical data from phase
83 I/II and larger mono- and multicentre case series regarding safety, feasibility, and oncologic
84 efficacy are encouraging. While the therapeutic role of PIPAC is still unclear [3], prospective
85 randomized PIPAC trials are underway and their results are eagerly awaited [4, 5].

86 For over a decade, only the original PIPAC nozzle was available for clinical use, with more
87 than 18`000 documented clinical applications worldwide were projected by the end of 2022 [3].
88 To ensure comparability of the outcome data, much efforts was spent to standardize PIPAC
89 therapy worldwide [6, 7]. But more recently, new nebulizer devices are also in clinical use.
90 While the technical and clinical performance data of the original PIPAC nozzle has been
91 extensively studied in pre- and clinical settings [3, 8, 9], no or only very limited comparative
92 data are available for the new PIPAC nozzles. Oncological surgeons around the world are now
93 faced with the question of whether these newer nozzles are equivalent to the original nozzle
94 technology or perhaps even have technical/functional advantages with a potentially better
95 oncological outcome?

96 On the basis of the methodological findings regarding the technical characterisation of the
97 original PIPAC nozzle [8], the current study deals with the comparative performance
98 characterisation of four commercial nebulizers as nowadays used for PIPAC.

99

100 **2 Materials and Methods**

101 **2.1 Examined PIPAC nozzles**

102 Four commercial single-substance PIPAC nozzles for intraperitoneal drug aerosolization were
103 examined, i.e.,

- 104 • Nebulizer, Model 770-12, REGER Medizintechnik, Villingendorf, Germany (A),

- 105 • HurriChem™, ThermaSolutions, White Bear Lake, MN, United States of America (B),
106 • MCR-4 TOPOL®, SKALA-Medica, Soběslav, Czech Republic (C),
107 • QuattroJet, Model 770-14, REGER Medizintechnik, Villingendorf, Germany (D).

108 After the experiments, all nozzles were cut-open longitudinally in the middle in a 180° angle
109 by means of a computerized numerical control milling machine to study their principles of
110 operation. In addition, also the dimensions of the nozzle outlet orifices were examined by light
111 microscopy (SMZ1500, Nikon, Tokyo, Japan).

112 2.2 *Barometric characterisation of operational pressure as function of liquid flow rate*

113 To characterise the operational pressure over the volumetric liquid flow rate, the nozzles were
114 connected via high-pressure hose lines with a high-pressure injector (ACCUTRON® HP-D,
115 MEDTRON AG, Saarbrücken, Germany) to push the test liquid (Glucosterile 5%, Fresenius
116 Kabi GmbH, Germany) through the nozzles. The operational pressure induced by the liquid
117 flow rate was determined by means of a glycerine-filled bourdon gauge (MA7U-25, JRA
118 Maschinenteile und Geräte GmbH, Reichenbach, Germany), which was implemented in the
119 high-pressure line. For the analyses, the volumetric liquid flow rate was increased stepwise
120 either by 0.1 ml/s (for nozzles A, B and D) or by 0.2 ml/s (for nozzle C) until the maximum
121 permitted pressure of 21 bar of the high-pressure injector was reached. For nozzle D, only the
122 axial nozzle was tested - the horizontal nozzles were sealed watertight. Analogous to [8],
123 measurement values were taken at steady state conditions of the aerosolization process and all
124 analyses were repeated three times.

125 2.3 *Granulometric characterisation of droplet size distributions*

126 The droplet size distributions of the aerosols generated from the test liquid (Glucosterile 5%,
127 Fresenius Kabi GmbH, Germany) were characterised by laser diffraction spectrometry
128 (PW180-C spray particle size analyser, Jinan K-Ring Technology Co., Ltd, Shandong, China)
129 over a size range of (0.57 - 780) µm. The outlets of the PIPAC nozzles were arranged via a
130 tripod in a distance of 5 mm perpendicular to the centre of the free-accessible red laser beam.
131 To characterise the aerosolization performance, all analyses were performed contemporaneous
132 with the barometric characterisation of the operational pressure for various liquid flow rates.
133 Analogous to [8], measurement values were taken at steady state conditions of the
134 aerosolization process and all analyses were repeated three times.

135 **2.4 Image-metric characterisation of spray cone angles, form and horizontal drug**
136 **deposition areas**

137 The spray cone angles, the form of the spray cones and the horizontal drug deposition area were
138 characterised with different test liquids at nozzle-specific operation conditions as recommended
139 by the manufacturers, i.e., at a volumetric liquid flow rate of 0.5 ml/s for the nozzles A, B, at
140 2.0 ml/s for nozzle C and 1.5 ml/s for nozzle D. The former two characteristics were evaluated
141 on the base of a 5 wt.-% aqueous glucose solution (Glucosterile 5%, Fresenius Kabi GmbH,
142 Germany), while the latter characteristic was assessed by operating the nozzles with undiluted
143 royal blue ink (Pelikan Tinte 4001[®], Hannover, Germany).

144 For the spray cone angle analyses, the nozzles were fixed on a tripod and vertically aligned.
145 Photographic images were taken with a camera that was perpendicular positioned to the nozzle
146 direction. The images were in-silico processed by overlaying with a digital 360° full-circle
147 protractor for determining the spray cone angles.

148 The form of the spray cones was visualized by means of a line laser (GCL 2-15, Robert Bosch
149 Power Tools GmbH, Leinfelden-Echterdingen, Germany) positioned in distance of 60 mm from
150 the nozzle orifice at right angle into the spray cone. Fully evaluated spray cone forms were
151 finally documented photographically.

152 The horizontal drug deposition on a level-aligned blotting paper was examined by operating the
153 vertically aligned nozzles with a distance of 60 mm between the blotting paper and the nozzle
154 orifice. The blotting paper was exposed for 3 s to the fully-developed spray jet. To achieve this,
155 a mechanical diaphragm was placed in front of the spray jet. The diaphragm was opened
156 automatically within 0.1 s, when the aerosol jet showed steady state nebulisation condition.

157 **2.5 Assessing of chemical resistance and chemical composition**

158 To assess the chemical resistance of the nozzle material against chemotherapeutic drugs, the
159 nozzles were at first exposed to a cytostatic solution for 12 hours and afterwards stored in the
160 dark at room temperature for 12 days within petri dishes. The chosen cytostatic solution was
161 prepared in accordance to the mixture of high pressure/high dose PIPAC (HP/HD-PIPAC) [10],
162 i.e., 6 mg of doxorubicin (Accord 2 mg/ml, Accord Healthcare GmbH, Munich, Germany) was
163 admixed with 50 ml of a 0.9 wt.-% aqueous sodium chloride solution (Ecolav[®] 100, B. Braun,
164 Melsungen, Germany). Finally, the nozzles were milled open in a laminar flow workbench and
165 macroscopic changes were documented photographically.


166 Moreover, the chemical composition of the nozzles pipes was characterised for the elements C,
167 Si, Mn, P, S, Cr, Ni, Mo, Cu, W and N by means of spark optical emission spectral analysis
168 (SPECTROMAXx, SPECTRO Analytical Instruments GmbH, Kleve, Germany) via an
169 accredited laboratory (WS Material Service GmbH, Essen, Germany).

170

171 3 Results

172 3.1 Technical design and principle of operation

173 The 90° sectional views of the head regions in Figure 1 show technical details of the examined
174 nozzles.



176 **Figure 1:** 90° sectional views of the head regions of the nozzles. Legend: O = outlet orifice; H = nozzle
177 head; I = bar inlay with distal transverse borehole; M = double metal grid; N = fixed needle; S = shaft;
178 T = twist body.


179 Externally, all nozzles consist of a stainless steel shaft (S) with a more or less pronounced nozzle
180 head (H) on the lower part and a Luer lock thread on the upper part (not shown in Figure 1).
181 The Luer lock threads serve for the connection of the nozzles with high-pressure injectors via
182 high-pressure hose lines. Internally, the nozzles show partly considerable differences.

183 Interestingly, nozzle A and B are quasi identical in construction and their principle of operation,
184 while the nozzles C and D differ significantly from them and from each other.

185 In the case of the nozzles A, B and D, the liquid drug is supplied internally from the Luer lock
186 connector to the nozzle head via an annular gap between the outer shaft (S) and a bar inlay with
187 distal transverse borehole (I). In contrast, the internal liquid drug supply of nozzle C occurs
188 directly via the hollow cavity of the shaft (S). Moreover, nozzle C is equipped with a double
189 metal grid (M) with two different mesh sizes that serve as particle filter.

190 While the nozzles A and B contain one twist body (T), nozzle D is equipped with four twist
191 bodies (i.e., with one axial and three lateral twist bodies in 120° arrangement) to improve the
192 spatial drug distribution within the abdominal cavity. The twist bodies (T) of the nozzles A, B
193 and D contain longitudinally superfcially milled grooves at 180° intervals. As the liquid drug
194 flow rate passes along the twist bodies (T) they were set into rotation that improves the
195 aerosolisation prior leaving the nozzle via the outlet orifice (O). In the case of nozzle C, the
196 twist body is replaced by an fixed metal needle (N). This needle contains also laterally located,
197 spirally milled axial grooves that induce a whirlwind effect for aerosolisation when passed by
198 the liquid flow before leaving the nozzle via the outlet orifice (O).

199 Light microscopic images of the outlet orifices (O) with determined orifice diameters of the
200 examined nozzles are shown in Figure 2.



201
202 **Figure 2:** Light microscopic images of the outlet orifices with determined orifice diameters of the
203 examined nozzles; scaling in mm.


204 3.2 Operational parameters based on barometric and granulometric analyses

205 Figure 3 a depicts at first the determined operational pressure over the liquid flow rate of the
206 examined nozzles, while in Figure 3 b the mass median diameter of the of the droplet size
207 distribution over the operational pressure is given. To avoid artefacts due clouding of the optics

208 of the laser diffraction spectrometer, the lateral nozzles of nozzle D (QuattroJet) were taped off
209 for the granulometric analyses and a flow rate of 0.5 ml/s was chosen (manufacturer-
210 recommended flow rate of 1.5 ml/s) Note that the shown data are determined at steady state
211 conditions of the aerosolization process analogous to [8].

212 It can be observed in Figure 3 a that the determined operational pressure data for all examined
213 nozzles fit well with the fluid dynamic theory, i.e., the dynamic pressure (or the dynamic
214 pressure drop) of an incompressible fluid increases with the fluid velocity by the power of two.
215 According to the equation of continuity, the fluid velocity of an incompressible fluid is in turn
216 directly proportional to the volumetric liquid flow rate. The nozzles A, B and D show a similar
217 performance regarding operational pressure and liquid flow rate, while nozzle C (MCR-4
218 TOPOL[®]) has a significantly lower pressure drop and thus a considerable higher volumetric
219 liquid flow rate at a specific operational pressure.

220 Beside the whole operational spectrum, also the manufacturer-recommended operational
221 conditions were separately examined, i.e., at a volumetric liquid flow rate of 0.5 ml/s for nozzle
222 A (Nebulizer), nozzle B (HurriChem[™]), (1.3 - 2.0) ml/s for nozzle C (MCR-4 TOPOL[®]) and
223 1.5 ml/s for nozzle D (QuattroJet). Under these preconditions nozzle C showed with (18 - 26) s
224 the shortest initiation time to reach the corresponding steady state pressure of (7.4 – 18.1) bar,
225 followed by nozzle A with 52 s (15.7 bar) and nozzle D with 94 s (16.0 bar). Note that with
226 taped-off lateral nozzles, nozzle D shows a higher operational pressure of 19.3 bar (as shown
227 in Figure 3).



228

229 **Figure 3:** Operational pressure as function of the liquid flow rate from barometric analyses (a), mass
 230 median diameter as function of the operational pressure from granulometric analyses (b) and volume-
 231 weighted distributions density (c) and cumulative distribution (d) of droplets at certain manufacturer-
 232 recommended operational condition; black cycles/ellipses indicate manufacturer-recommended
 233 operation condition.


234 Figure 3 b shows that the mass median diameter of the generated droplet aerosols depends for
 235 each nozzle significantly on the operational pressure. With increasing operational pressure, the
 236 mass median diameter decreases. For operational pressures of ≤ 4 bar, quasi no significant
 237 difference between the different nozzles can be observed. This is attributed to a non-fully
 238 developed aerosolization of the supplied liquid. For operation pressures of ≥ 5 bar stable aerosol

239 generation is reached and differences between the nozzles can be observed. For operational
240 pressures ≥ 5 bar, nozzle C (MCR-4 TOPOL[®]) shows the coarsest mass median diameters,
241 followed by nozzle A (Nebulizer). The finest mass median diameters were determined for
242 nozzle B (HurriChem[™]) and D (QuattroJet).

243 This ranking can also be deduced by the volume-weighted droplet size distributions of the
244 aerosols as generated by the nozzles at the manufacturer-recommended operation conditions
245 (Figure 3 c, Figure 3 d). Moreover, it can be observed in Figure 3 c and Figure 3 d, that each
246 aerosol has a polydisperse and bimodal droplet size distribution.

247 3.3 Operational parameters based on image-metric analyses

248 Figure 4 shows photographic images for the spray cone angle (upper panel), the spray cone
249 form (mid panel) and the horizontal drug deposition area (lower panel) of each examined nozzle
250 as determined at manufacturer-recommended operational conditions.



251

252 **Figure 4:** Photographic images of spray cone angle (upper panel), of spray cone form (middle panel)
253 and horizontal drug deposition area (lower panel, scale in cm).

254 According to the upper panel of Figure 4, the widest single spray cone angle was determined
255 with 79° for nozzle C (MCR-4 TOPOL[®]), followed with 72° for nozzle A (Nebulizer) and with
256 71° for nozzle B (HurriChem[™]). Nozzle D (QuattroJet) shows with 67° the smallest single
257 spray cone angle, but it has to keep in mind that nozzle D contains in contrast to the other
258 nozzles of four spray cones. Moreover, it can be observed from the middle panel of Figure 4
259 that nozzle A (Nebulizer), nozzle B (HurriChem[™]) and nozzle D (QuattroJet) generate a full
260 spray cone, whereas nozzle C (MCR-4 TOPOL[®]) produces a hollow spray cone. The full spray
261 cones of the nozzles A, B and C lead also to complete filled circular areas of horizontal drug
262 deposition beneath the nozzles as shown in the lower panel of Figure 4. In the case of the nozzles
263 A and B, a circular deposition area of approx. 38.5 cm^2 (outer diameter of approx. 7 cm) was
264 determined. The lateral outlets of nozzle D showed beside the axial circle (outer diameter of
265 approx. 7 cm) also 3 additional deposition areas of $(13 \times 20) \text{ cm}$ that cumulates to an overall
266 horizontal deposition area of approx. 679 cm^2 .

267 3.5 *Chemical resistance and chemical composition*

268 Photographic images of the nozzle parts after the exposure to the cytostatic solution are shown
269 in Figure 5.



270
271 **Figure 5:** Photographic images of the nozzle parts after exposure to the cytostatic solution.

272 Figure 5 shows that in the case of nozzle C (MCR-4 TOPOL[®]) the exposure to the cytostatic
273 solution led to the formation of iron oxide. These are particularly pronounced on the fine-mesh
274 particle filter, the nozzle needle and the nozzle head housing. No changes were observed for
275 the nozzles A, B and D either visually or by light microscopic analyses.

276 The nozzles A, B and D fulfil all requirements according to EN 10088-3:2014 [11] on the
277 chemical composition of stainless steel 1.4301 that is typically used for surgical instruments.

278 Beside a twelve times higher quantity of sulphur (0.012 wt.-% vs. 0.001wt.-%), also quantities
279 of molybdenum (0.183 wt.-%), copper (0.220 wt.-%) and tungsten (0.134wt.-%) were
280 identified by spark optical emission spectrometry for nozzle C (MCR-4 TOPOL®).

281

282 4 Discussion

283 Due to the current lack of knowledge, four clinically-operated nebulising nozzles for PIPAC
284 were comparatively tested regarding their performance. The most important determined
285 technical characteristics of these nozzles are summarised in Table 1.

286 **Table 1:** Overview on technical and functional characteristics of the examined nozzles; * =
287 manufacturer-recommended operational conditions.

parameter	unit	A (Nebulizer)	B (HurriChem™)	C (MCR-4 TOPOL®)	D (QuattroJet)
*liquid flow rate (*Q _L)	ml/s	0.5	0.5	1.3 - 2.0	1.5
operational pressure for *Q _L	bar	15.7	14.9	7.4 – 18.1	16.0
pressure initiation time for *Q _L	s	52	100	18 - 26	94
nozzle orifice diameter	µm	200	190	370	170
mass median diameter for 15 bar	µm	28.95	20.99	52.17	24.18
max. spray angle for *Q _L	°	≈ 72	≈ 71	≈ 79	≈ 67
number of nozzles	-	1 × axial	1 × axial	1 × axial	1 × axial, 3 × lateral
kind of spray cone	-	full cone	full cone	hollow cone	full cone
drug deposition area for *Q _L	cm ²	≈ 38.5	≈ 38.5	≈ 66	≈ 679

288

289 Nozzle A (Nebulizer) shows after an initiation time of 52 s an operational pressure of 15.7 bar
290 at the manufacturer-recommended operational liquid flow rate of 0.5 ml/s. Thereby, a full spray
291 jet cone (71°) composed of droplets with a mass median diameter of 29 µm is formed. The
292 determined data of this study reveal that nozzle A is identical in design and performance to the
293 primary for PIPAC developed predecessor, i.e., the microinjection pump MIP [8], which was
294 also distributed under the tradename CapnoPen.

295 Nozzle B (HurriChem™) is another launched nebulizer for PIPAC. Examinations on design
296 and principle of operation show a high similarity with nozzle A (Nebulizer) and thus also with
297 the initial PIPAC nozzle technology. At the manufacturer-recommended operational liquid flow
298 rate of 0.5 ml/s, nozzle B shows after an initiation time of 100 s an operational pressure of

299 14.9 bar. The mass median diameter of the droplets in the formed full spray jet cone (73°) was
300 determined to be 21 µm.

301 Nozzle C (MCR-4 TOPOL®) differs in technical design, principle of operation, operational
302 parameter and aerosol characteristics significantly from all other investigated nozzles. The
303 operation of nozzle C is accompanied by the formation of a hollow spray cone jet (79°). At the
304 manufacturer-recommended operational liquid flow rate range of (1.3 – 2.0) ml/s, operational
305 pressures of (7.4 – 18.1) bar were reached within short initiation times of (18 – 26) s. The mass
306 median droplet size decreases with increasing liquid flow rate, but was found to be in each case
307 larger than 50 µm.

308 Nozzle D (QuattroJet) is a further PIPAC nebulizing nozzle that was introduced by the
309 manufacturer of nozzle A. To optimize the spatial drug distribution pattern and higher
310 intraabdominal aerosol particle concentration, the conventional axial nozzle is supplemented in
311 nozzle D by three further nozzles, which are arranged lateral at the nozzle head with an angular
312 distance of 120°. Nozzle D is based on the same technology as nozzle A. At the manufacturer-
313 recommended flow rate of 1.5 ml/s, nozzle D shows an operational pressure of 16.0 bar after
314 an initiation time of 92 s and provides four full spray cone jets (67°) composed of droplets with
315 a mass median diameter of 21 µm.

316 Recently, a first attempt regarding recommendations on the minimum technical requirements
317 on nozzles suitable for PIPAC treatment was published. A minimum requirement for the spray
318 angle of at least 70° was defined [12] by implying that the spray cone angle corresponds to the
319 achievable drug deposition area. But there are two limitations found in this study that contradict
320 this requirement. The present study shows that the requirement is matched directly by nozzle
321 A, B and C. But despite of a slightly lower spray cone angle of 67° than required, nozzle D
322 consists of four spatially-displaced spray jets cumulating in a total spray angle of 268°. On the
323 other hand, Nozzle C, unlike all other nozzles examined, had a hollow spray cone, resulting in
324 a ring-shaped drug deposition area that was smaller than that of a full spray cone jet at the same
325 spray cone angle. With regard on the nozzle performance, the drug deposition area seems to be
326 an even better technical parameter than the spray cone angle.

327 The examined nozzles C (MCR-4 TOPOL®) and D (QuattroJet) of this study show in contrast
328 to A (Nebulizer) and B (HurriChem™) and thus in contrast to the primary PIPAC nozzle
329 technology significant differences in their principle of operation and performance. Nozzle C

330 offers the largest spray cone angle of all examined nozzles, but also a hollow spray cone. It is
331 not evident if such a spray jet improves drug distribution and drug penetration, since so far as
332 known there are no preclinical studies comparing a hollow with a full spray cone. Nozzle D
333 provides multiple spray cones that can significantly improve the spatial drug distribution by
334 reduction of high local deposition and thus high local tissue toxicity. Nonetheless, these
335 potential benefits of multi-nozzle systems need to be confirmed by further research.

336 A worrying result of this study was, that nozzle C (MCR-4 TOPOL[®]) shows in contrast to the
337 other nozzles a macroscopically visible formation of iron oxide after long-term exposure in a
338 sodium chloride containing cytostatic solution. Based on spark optical emission spectrometry,
339 it was found that this nozzle was made from a steel that, in addition to a 12-fold higher sulphur
340 content (0.012 wt.-% vs. 0.001 wt.-%), also contained amounts of molybdenum (0.183 wt.-%),
341 copper (0.220 wt.-%) and tungsten (0.134 wt.-%). Short-term exposure of the nebulizers to
342 cytostatic solution shows no immediate corrosion, but a possible risk for the patient cannot be
343 completely ruled out. This leads to the conclusion that manufacturer and regulatory authorities
344 for medical devices accreditation must also critically assess the suitability of specific steel
345 alloys for the administration of cytostatic drugs in their risk assessment.

346 Currently, there are only limited preclinical data to suggest that there is an optimal technique
347 for the generation and delivery of PIPAC aerosols that could improve clinical outcome.
348 However, it is clear that, contrary to claims made by one manufacturer [13], larger aerosol
349 droplets injected into the peritoneal cavity at higher velocities with a hollow spray cone do not
350 improve either the spatial distribution pattern [8, 14] or tissue penetration depth per se.
351 Nebulizers differing from the present standard technology in its design, especially in its
352 spraying characteristics, cannot automatically be considered equivalent by the clinical user.
353 Therefore, before their broad clinical use, the individual innovation phases should be
354 systematically tested, ideally following the recommendation of the IDEAL-D framework for
355 the introduction of medical devices [15, 16]. While the original nozzle technology has
356 completed phase I - IIb [17] and phase III trials are ongoing [4, 5], only limited phase I clinical
357 user data has been published for nozzle C (MCR-4 Topol[®]) [18]. Such data are lacking for
358 nozzle B and D.

359 In the near future, clinical users should be able to rely on technical testing and reporting being
360 based on scientific standards and generally applicable global standards, such as ISO standards.
361 For PIPAC nebulizers, such standards should ideally be set by a panel of experts through

362 consensus conferences. Moreover, nebulizers with significant technical and granulometric
363 differences from the standard technology should undergo first ex- and in-vivo animal testing
364 before their first clinical use. Manufacturers should be obliged to have the bioequivalence of
365 the cytostatic drugs administered independently certified in comparison to standard nebulizer
366 systems, analogous to drugs and their generics. Relevant outcome measures are aerosol
367 characteristics, spatial drug distribution, depth of penetration, tissue concentration and the peak
368 concentration and the area under the curve describing the extent of peritoneal passage [8, 19 -
369 28]. The ratio between the individual properties of the generic nebulizer and the reference
370 product would ideally be 1:1 in case of bioequivalence. Since this is unlikely to be achieved,
371 the US Food and Drug Administration (FDA), for example, requires that the 90% confidence
372 interval should be between 0.80 and 1.25 [29]. Similar to the FDA specifications, new PIPAC
373 nozzle technologies could be tested comparatively in the future. Such preclinical testing, ideally
374 using standardized models, could prevent the use of such devices from compromising clinical
375 outcomes and/or harming healthcare professionals/patients. Finally, it would be helpful for the
376 comparability of clinical results if the nebulizer type used in each case will be also recorded in
377 the PIPAC database (<https://isspp.org/professionals/pipac-database/>).

378

379 **5 Conclusion**

380 Four clinically-used nozzles to aerosolise chemotherapeutic drugs in the context of Pressurized
381 Intraperitoneal Aerosol Chemotherapy (PIPAC), i.e., the Nebulizer, the HurriChem™, the
382 MCR-4 TOPOL® and the QuattroJet were examined comparative to determine their
383 performance.

384 It could be confirmed that the Nebulizer shows quasi an identical technical design and thus also
385 a similar performance as the original PIPAC nozzles MIP/CapnoPen. The PIPAC nozzle
386 HurriChem™ is based on a similar technical design as the Nebulizer nozzle, but provides a
387 finer aerosol due to a smaller nozzle orifice opening. Both, the MCR-4 TOPOL® and the
388 QuattroJet deviate in the principles of operations to that of the Nebulizer and thus to the original
389 PIPAC technology. While the MCR-4 TOPOL® provides the coarsest aerosol of all examined
390 nozzles, the QuattroJet delivers an aerosol similar to that of the HurriChem™. In contrast to the
391 HurriChem™, the QuattroJet® comes with the feature of four spray cones (one axial, three
392 lateral) to improve the spatial drug distribution and a higher aerosol particle number
393 concentration.

394 The availability of new PIPAC nozzles with special features is encouraging, but can also have
395 a negative impact for establishment of the promising PIPAC approach for the treatment of
396 peritoneal carcinomatosis, if their performance and efficacy is unknown. It is therefore
397 recommended that nozzles for which the technical/granulometric characteristics differ from the
398 current standard technology must be subjected to preclinical proof of equivalence in terms of
399 spatial drug distribution, tissue penetration and concentration before routine clinical use. It is
400 expected that representative in-silico models like the ones used in [23, 24] will be available in
401 the near future. New nebulizers should be investigated and introduced for clinical use in
402 accordance with the IDEAL-D framework.

403

404 **References**

- 405 1. Solaß W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA Description of a novel
406 approach for intraperitoneal drug delivery and the related device. *Surg. Endosc.*
407 2012;26(7):1849–1855. Doi: 10.1007/s00464-012-2148-0.
- 408 2. Solaß W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal
409 carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence
410 for efficacy. *Ann. Surg. Oncol.* 2014;21(2):553–559. Doi: 10.1245/s10434-013-3213-1.
- 411 3. Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy:
412 rationale, evidence, and potential indications. *Lancet Oncol.* 2019;20(7):e368–e377. Doi:
413 10.1016/S1470-2045(19)30318-3
- 414 4. Somashekhar SP, Ashwin KR, Rauthan A, Rohit KC Pressurized IntraPeritoneal Aerosol
415 Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases
416 secondary to platinum resistant ovarian cancer – study protocol for a randomized control
417 trial. *Pleura and Peritoneum* 2019;4(1). Doi: 10.1515/pp-2018-0111
- 418 5. Casella F, Bencivenga M, Rosati R, et al. Pressurized intraperitoneal aerosol chemotherapy
419 (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer:
420 a randomized multicenter phase III trial PIPAC VEROne. *Pleura and Peritoneum*
421 2022;7(3):135–141. Doi: 10.1515/pp-2022-0111
- 422 6. Sgarbura O, Villeneuve L, Alyami M, et al. Current practice of pressurized intraperitoneal
423 aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?
424 *European Journal of Surgical Oncology* 2021;47(1):149–156. Doi:
425 10.1016/j.ejso.2020.08.020
- 426 7. Sgarbura O, Eveno C, Alyami M, et al. Consensus statement for treatment protocols in
427 pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Pleura and Peritoneum*
428 2022;7(1):1–7. Doi: 10.1515/pp-2022-0102
- 429 8. Göhler D, Khosrawipour V, Khosrawipour T, et al. Technical description of the micro
430 injection pump (MIP®) and granulometric characterization of the aerosol applied for
431 Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). *Surg. Endosc.*
432 2017;31(4):1778–1784. Doi: 10.1007/s00464-016-5174-5
- 433 9. Nadiradze G, Horvath P, Sautkin Y, et al. Overcoming Drug Resistance by Taking
434 Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy
435 (PIPAC). *Cancers* 2020;12(1):34. Doi: 10.3390/cancers12010034.

- 436 10. Arias GR, Sindaigaya R, Ouaiissi M, et al. Safety and Feasibility of High-Pressure/High-
437 Dose Pressurized Intraperitoneal Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and
438 Metastatic Peritoneal Surface Malignancies. *Ann. Surg. Oncol.* 2022. Doi: 10.1245/s10434-
439 022-12698-4.
- 440 11. EN 10088-3:2014. Stainless steels - Part 3: Technical delivery conditions for semi-finished
441 products, bars, rods, wire, sections and bright products of corrosion resisting steels for
442 general purpose.
- 443 12. Pocard M, So JBY, Huchon C, et al. PIPAC nebulizer: How to test the new devices in the
444 market, expert recommendations. *Journal of Visceral Surgery* 2022. Doi:
445 10.1016/j.jviscsurg.2022.10.001.
- 446 13. PIPAC – Pressurized Intraperitoneal Aerosol Chemotherapy; [https://www.skala.cz/en/mcr-
447 4-topol-en/](https://www.skala.cz/en/mcr-4-topol-en/) (access: 5th March 2023 at 11:02 CET)
- 448 14. Hinds, William C. (1999). *Aerosol technology: properties, behaviour, and measurement of*
449 *airborne particles*. New York: Wiley. ISBN 978-0-471-19410-1.
- 450 15. Sedrakyan A, Campbell B, Merino JG, Kuntz R, Hirst A, McCulloch P IDEAL-D: a rational
451 framework for evaluating and regulating the use of medical devices. *Br. Med. J.* 2016;i2372.
452 Doi: 10.1136/bmj.i2372.
- 453 16. Páez A, Rovers M, Hutchison K, Rogers W, Vasey B, McCulloch P Beyond the RCT: When
454 are Randomized Trials Unnecessary for New Therapeutic Devices, and What Should We
455 Do Instead? *Ann. Surg.* 2021;275(2):324–331. Doi: 10.1097/SLA.0000000000005053.
- 456 17. Baggaley AE, Lafaurie GBRC, Tate SJ, et al. Pressurized intraperitoneal aerosol
457 chemotherapy (PIPAC): updated systematic review using the IDEAL framework. *Br. J.*
458 *Surg.* 2022;110(1):10–18. Doi: 10.1093/bjs/znac284.
- 459 18. Hoskovec D, Dytrych P, Vocka M, Krska Z, Skala R MCR-4 TOPOL® new device for
460 PIPAC – first clinical use. *Eur. J. Surg. Oncol.* 2022;48(2):e155. Doi:
461 10.1016/j.ejso.2021.12.308.
- 462 19. Rahimi-Gorji M, Debbaut C, Ghorbaniasl G, Cosyns S, Willaert W, Ceelen W Optimization
463 of Intraperitoneal Aerosolized Drug Delivery: A Computational Fluid Dynamics (CFD) and
464 Experimental Study. *Scientific Reports* 2021;12(1). Doi: 10.1038/s41598-022-10369-8.
- 465 20. Göhler D, Geldner A, Gritzki R, et al. Development of a rat capnoperitoneum phantom
466 (RCP) to study drug aerosol deposition in the context of anticancer research on peritoneal
467 carcinomatosis. *Sci. Rep.* 2021;11:21843. Doi: 10.1038/s41598-021-01332-0.

- 468 21. Göhler D, Große S, Bellendorf A, et al. Hyperthermic intracavitary nano-aerosol therapy
469 (HINAT) as improved approach for pressurised intraperitoneal aerosol chemotherapy
470 (PIPAC): Technical description, experimental validation and first proof of concept.
471 Beilstein J. Nanotechnol. 2017;8:2729–2740. Doi: 10.3762/bjnano.8.272.
- 472 22. Buggisch JR, Göhler D, Sobilo J, et al. Development and technical validation of an
473 ultrasound nebulizer to deliver intraperitoneal pressurized aerosols in a rat colon cancer
474 peritoneal metastases model. BMC Cancer 2022;22(570). Doi: 10.1186/s12885-022-09668-
475 0.
- 476 23. Rezniczek GA, Buggisch J, Sobilo J, et al. Establishment of a mouse ovarian cancer and
477 peritoneal metastasis model to study intraperitoneal chemotherapy. Cancers 2020;12(12).
478 Doi: 10.3390/cancers12123818.
- 479 24. Höltzcke P, Sautkin I, Clere S, Castagna A, Königsrainer A, Pott PP, Reymond MA.
480 Feasibility of pressurized intra peritoneal aerosol chemotherapy using an ultrasound aerosol
481 generator (usPIPAC). Surg Endosc. 2022 Oct;36(10):7848-7858. doi: 10.1007/s00464-022-
482 09525-y. Epub 2022 Aug 29. PMID: 36038646; PMCID: PMC9485099.
- 483 25. Toussaint L, Sautkin Y, Illing B, Weinreich FJ, Nadiradze G, Königsrainer A, Wichmann
484 D. Correction to: Comparison between microcatheter and nebulizer for generating
485 Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Surg Endosc. 2021
486 Aug;35(8):4901. doi: 10.1007/s00464-021-08577-w. Erratum for: Surg Endosc. 2021
487 Apr;35(4):1636-1643. PMID: 34106308; PMCID: PMC8263410.
- 488 26. Mun J, Park SJ, Kim HS. Rotational intraperitoneal pressurized aerosol chemotherapy in a
489 porcine model. Gland Surg. 2021 Mar;10(3):1271-1275. doi: 10.21037/gs-2019-ursoc-11.
490 PMID: 33842275; PMCID: PMC8033043.
- 491 27. Mimouni, M., Richard, C., Adenot, P. et al. Pressurized intra-peritoneal aerosol
492 chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution
493 patterns but leads to deeper penetration depth of doxorubicin in a sheep model. BMC Cancer
494 21, 461 (2021). <https://doi.org/10.1186/s12885-021-07955-w>
- 495 28. Giger-Pabst, U., Bucur, P., Roger, S. et al. Comparison of Tissue and Blood Concentrations
496 of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann
497 Surg Oncol 26, 4445–4451 (2019). <https://doi.org/10.1245/s10434-019-07695-z>
498

- 499 29. Andrade C Bioequivalence of Generic Drugs: A Simple Explanation for a US Food and
500 Drug Administration Requirement. *Journal of Clinical Psychiatry* 2015;76(06):e742–e744.
501 Doi: 10.4088/JCP.15f10094.